Regional WHO HPV Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Melbourne, Australia.
Int J Gynaecol Obstet. 2012 Apr;117(1):30-2. doi: 10.1016/j.ijgo.2011.11.022. Epub 2012 Feb 10.
Prophylactic human papillomavirus (HPV) vaccines are currently not available in Papua New Guinea. Prior to introducing these vaccines, knowledge about the HPV genotypes present in cervical cancer in this region is necessary to determine whether the types covered by the 2 commercially licensed vaccines are the same as those in other regions of the world.
Fresh, frozen cervical biopsies from 70 women with cervical cancer in Papua New Guinea were collected over a 3-year period from 2006-2009. HPV genotypes were detected using the Genera PapType assay.
Overall, 100% of the specimens were HPV DNA positive, with HPV types 16 and 18 being the most prevalent at 57.1% and 25.7% (95% CI, 0.45-0.68 and 0.17-0.37) respectively, followed by HPV 33 (10%; 95% CI, 0.05-0.19) and HPV 31 (4.3%; 95% CI, 0.01-0.12). Multiple genotypes were identified in 6 women (8.6%), with all biopsies containing HPV 16 and 1 other high-risk type.
The 2 most prevalent HPV types identified in women with cervical cancer in Papua New Guinea correspond to global data. This suggests that the currently available HPV vaccines could potentially reduce the burden of HPV-related cervical cancer in Papua New Guinea significantly.
巴布亚新几内亚目前没有预防性人乳头瘤病毒（HPV）疫苗。在引入这些疫苗之前，需要了解该地区宫颈癌中存在的 HPV 基因型，以确定两种商业许可疫苗涵盖的类型是否与世界其他地区的类型相同。
2006-2009 年期间，在 3 年内从巴布亚新几内亚的 70 名宫颈癌妇女中采集了新鲜的、冷冻的宫颈活检标本。使用 Genera PapType 检测法检测 HPV 基因型。
总体而言，100%的标本 HPV DNA 阳性，HPV 16 型和 18 型最为常见，分别为 57.1%和 25.7%（95%CI，0.45-0.68 和 0.17-0.37），其次是 HPV 33（10%；95%CI，0.05-0.19）和 HPV 31（4.3%；95%CI，0.01-0.12）。6 名妇女（8.6%）确定了多种基因型，所有活检均含有 HPV 16 型和 1 种其他高危型。
在巴布亚新几内亚宫颈癌妇女中发现的两种最常见的 HPV 类型与全球数据相符。这表明，目前可用的 HPV 疫苗有可能显著降低巴布亚新几内亚 HPV 相关宫颈癌的负担。
